[
  {
    "ts": null,
    "headline": "Could This Potential Move Boost Eli Lilly's Prospects?",
    "summary": "The stock already looks unstoppable, and this move won't hurt its momentum.",
    "url": "https://finnhub.io/api/news?id=2fc675d964d2e32604d6654763b05bdb0e7ea9cc58ee2f2ed953cd76a085241e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767198000,
      "headline": "Could This Potential Move Boost Eli Lilly's Prospects?",
      "id": 137950157,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The stock already looks unstoppable, and this move won't hurt its momentum.",
      "url": "https://finnhub.io/api/news?id=2fc675d964d2e32604d6654763b05bdb0e7ea9cc58ee2f2ed953cd76a085241e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer and GSK Lead 2026 U.S. Drug Price Hikes",
    "summary": "Drugmakers Brace for January Price Changes",
    "url": "https://finnhub.io/api/news?id=95b88e732bb8e7176de68e7270af3ce204571056f7f6e8ffcfcfc07d9bc74031",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767196981,
      "headline": "Pfizer and GSK Lead 2026 U.S. Drug Price Hikes",
      "id": 137950158,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Drugmakers Brace for January Price Changes",
      "url": "https://finnhub.io/api/news?id=95b88e732bb8e7176de68e7270af3ce204571056f7f6e8ffcfcfc07d9bc74031"
    }
  },
  {
    "ts": null,
    "headline": "Vanda Jumps 21% After FDA Approves Motion Sickness Therapy",
    "summary": "FDA approves Vanda's Nereus, developed with Eli Lilly, supported by three pivotal clinical trials.",
    "url": "https://finnhub.io/api/news?id=74cb93c2e5d312f34e6b6d7b0fb474d8365ddfbd431dc1c45e2fc9b9825cf908",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767196638,
      "headline": "Vanda Jumps 21% After FDA Approves Motion Sickness Therapy",
      "id": 137950159,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "FDA approves Vanda's Nereus, developed with Eli Lilly, supported by three pivotal clinical trials.",
      "url": "https://finnhub.io/api/news?id=74cb93c2e5d312f34e6b6d7b0fb474d8365ddfbd431dc1c45e2fc9b9825cf908"
    }
  },
  {
    "ts": null,
    "headline": "Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval",
    "summary": "The FDA approved Vanda’s drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked to GLP-1 weight-loss drugs.",
    "url": "https://finnhub.io/api/news?id=7778c978ba5f763d475e4750be38ba880abdefef0d58fd864d17c7ca11d5665e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767196620,
      "headline": "Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval",
      "id": 137950160,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The FDA approved Vanda’s drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked to GLP-1 weight-loss drugs.",
      "url": "https://finnhub.io/api/news?id=7778c978ba5f763d475e4750be38ba880abdefef0d58fd864d17c7ca11d5665e"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: Craft Beers Enter 2026 On Choppy Waters",
    "summary": "With libations already flowing around the globe to ring in the New Year, itâs a good time to ask what 2026 holds for craft beer.",
    "url": "https://finnhub.io/api/news?id=0cb018d2a96d3b6bd7b5d7ccb1fda2341c61709bddf7d1be5acb99be76cf5aa0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767194459,
      "headline": "Wall Street Lunch: Craft Beers Enter 2026 On Choppy Waters",
      "id": 137952601,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1295737155/image_1295737155.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "With libations already flowing around the globe to ring in the New Year, itâs a good time to ask what 2026 holds for craft beer.",
      "url": "https://finnhub.io/api/news?id=0cb018d2a96d3b6bd7b5d7ccb1fda2341c61709bddf7d1be5acb99be76cf5aa0"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs",
    "summary": "List prices to rise an average of 4% despite federal pressure to curb costs.",
    "url": "https://finnhub.io/api/news?id=99a41ad6d5957640fad350a769e0fb968bc194a5106242f6b7878d63c84d7775",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767191682,
      "headline": "Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs",
      "id": 137950161,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "List prices to rise an average of 4% despite federal pressure to curb costs.",
      "url": "https://finnhub.io/api/news?id=99a41ad6d5957640fad350a769e0fb968bc194a5106242f6b7878d63c84d7775"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures Fall On 2025's Final Day; Eli Lilly, Shopify Forge Buy Points",
    "summary": "The stock market will enter the final day of 2025 near highs — and key support. Shopify, Eli Lilly have forged new buy points.",
    "url": "https://finnhub.io/api/news?id=f96a4ac5fba999c8913628b68ac8b0087c90bdd0ca064230de591a28df13ff01",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767186575,
      "headline": "Dow Jones Futures Fall On 2025's Final Day; Eli Lilly, Shopify Forge Buy Points",
      "id": 137950162,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The stock market will enter the final day of 2025 near highs — and key support. Shopify, Eli Lilly have forged new buy points.",
      "url": "https://finnhub.io/api/news?id=f96a4ac5fba999c8913628b68ac8b0087c90bdd0ca064230de591a28df13ff01"
    }
  },
  {
    "ts": null,
    "headline": "VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains",
    "summary": "Vanda stock jumps after FDA approves tradipitant as Nereus for motion sickness, marking the first new therapy in over 40 years and boosting investor optimism.",
    "url": "https://finnhub.io/api/news?id=154033932d86ff83ad83e8a758c861032843c0c32a61962cd9018b8b9b3c9955",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767184560,
      "headline": "VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains",
      "id": 137950163,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Vanda stock jumps after FDA approves tradipitant as Nereus for motion sickness, marking the first new therapy in over 40 years and boosting investor optimism.",
      "url": "https://finnhub.io/api/news?id=154033932d86ff83ad83e8a758c861032843c0c32a61962cd9018b8b9b3c9955"
    }
  }
]